Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Drug utilization and cost for erythropoiesis-stimulating agents in a long-term care resident population with chronic kidney disease.

Lafeuille MH, Bailey RA, Vekeman F, Kilpatrick BS, Senbetta M, Piech CT, Lefebvre P.

Consult Pharm. 2010 Aug;25(8):493-500. doi: 10.4140/TCP.n.2010.493.

PMID:
20736158
2.

Drug utilisation and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database.

Vekeman F, McKenzie RS, Bookhart BK, Laliberté F, Duh MS, Tak Piech C, Lefebvre P.

J Med Econ. 2009 Mar;12(1):1-8. doi: 10.3111/13696990802648167.

PMID:
19450059
3.

Propensity score matched assessment of treatment patterns and cost of erythropoiesis stimulating agent treatment in patients with cancer receiving myelosuppressive chemotherapy.

Tunceli O, Bailey RA, Stephenson JJ, Singer J.

J Oncol Pharm Pract. 2013 Dec;19(4):305-14. doi: 10.1177/1078155212466123. Epub 2012 Dec 12.

PMID:
23235918
4.

Utilization and cost comparison of erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.

Lafeuille MH, Bailey RA, Vekeman F, Scott McKenzie R, Lefebvre P.

J Med Econ. 2012;15(2):352-60. doi: 10.3111/13696998.2011.649326. Epub 2012 Jan 9.

PMID:
22168787
5.

Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations.

Duh MS, Mody SH, Scott McKenzie R, Lefebvre P, Gosselin A, Tak Piech C.

Clin Ther. 2006 Sep;28(9):1443-50.

PMID:
17062316
6.

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia.

Pashos CL, Larholt K, Fraser KA, McKenzie RS, Senbetta M, Piech CT.

Support Care Cancer. 2012 Jan;20(1):159-65. doi: 10.1007/s00520-010-1083-7. Epub 2011 Feb 27.

7.

Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in anemic predialysis chronic kidney disease patients from an observational study.

Papatheofanis F, Smith C, Mody S, McKenzie RS, Bookhart B, Piech CT.

Am J Ther. 2007 Jul-Aug;14(4):322-7.

PMID:
17667204
8.

Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations.

Duh MS, Mody SH, McKenzie RS, Lefebvre P, Gosselin A, Bookhart BK, Piech CT.

Drugs Aging. 2006;23(12):969-76.

PMID:
17154661
10.

Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia.

Papatheofanis FJ, McKenzie RS, Mody SH, Suruki RY, Piech CT.

Curr Med Res Opin. 2006 May;22(5):837-42.

PMID:
16709305
11.

Dosing patterns, drug costs, and hematologic outcome in anemic patients with chronic kidney disease switching from darbepoetin alfa to epoetin alfa.

Hymes J, Bickimer T, Jackson JH, Bookhart BK, Mody SH, Tak Piech C.

Curr Med Res Opin. 2007 Aug;23(8):1931-7. Review.

PMID:
17624232
12.

The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia.

Ben-Hamadi R, Duh MS, Aggarwal J, Henckler A, McKenzie RS, Tak Piech C.

Curr Med Res Opin. 2005 Oct;21(10):1677-82.

PMID:
16238908
13.

Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations.

Lefebvre P, Gosselin A, McKenzie RS, Mody SH, Piech CT, Duh MS.

Curr Med Res Opin. 2006 Sep;22(9):1623-31.

PMID:
16968565
14.

Health economic evaluation of treating anemia in cancer patients receiving chemotherapy: a study in Belgian hospitals.

Spaepen E, Demarteau N, Van Belle S, Annemans L.

Oncologist. 2008 May;13(5):596-607. doi: 10.1634/theoncologist.2007-0219.

15.

Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.

Maddux FW, Shetty S, del Aguila MA, Nelson MA, Murray BM.

Ann Pharmacother. 2007 Nov;41(11):1761-9. Epub 2007 Sep 25.

PMID:
17895328
16.

Cost analysis: treatment of chemotherapy-induced anemia with erythropoiesis-stimulating agents in five European countries.

Duran A, Spaepen E, Lamotte M, Walter E, Umuhire D, Lucioni C, Pinheiro B, Brosa M, Kutikova L, Pujol B, Van Belle S, Annemans L.

J Med Econ. 2012;15(3):409-18. doi: 10.3111/13696998.2011.653597. Epub 2012 Jan 13.

PMID:
22208527
17.

Cost analytic model to determine the least costly inpatient erythropoiesis stimulating therapy regimen.

Sikand H, Decter A, Greco T, Watson SH, Kang YJ, Mody SH, Piech CT, Duh MS, Naeem A.

Ann Pharmacother. 2008 Jan;42(1):16-23.

PMID:
18029428
18.

Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents.

Mark TL, McKenzie RS, Fastenau J, Piech CT.

Curr Med Res Opin. 2005 Sep;21(9):1347-54.

PMID:
16197652
19.

Cost analysis of erythropoietic-stimulating therapy dosing in oncology inpatients.

Killian AD, Gupta V, Goetz AE.

Ann Pharmacother. 2006 Mar;40(3):421-6. Epub 2006 Feb 28.

PMID:
16507613
20.

Estimate of maintenance EPO to darbepoetin alfa dose conversion ratio in a hospital-based dialysis patient population.

Sharma A, Yee J, Gandra SR, Khan I, Petersen J.

Curr Med Res Opin. 2010 Nov;26(11):2679-87. doi: 10.1185/03007995.2010.526598. Epub 2010 Oct 13.

PMID:
20942616

Supplemental Content

Support Center